Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Obesity and Semaglutide in Type 1 Diabetes Therapy: A Multicentre, Randomised, Double-Blinded, Placebo-Controlled, Investigator-Initiated Trial

NCT06909006 is registered in ClinicalTrials.gov with Nordsjaellands Hospital as lead sponsor.

NCT NCT06909006
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06909006 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Obesity and Semaglutide in Type 1 Diabetes Therapy: A Multicentre, Randomised, Double-Blinded, Placebo-Controlled, Investigator-Initiated Trial
Lead sponsor
Nordsjaellands Hospital
Phase
Phase 3
Overall status
Not yet recruiting
Start date
October 31, 2025
Completion date
June 30, 2028
Enrollment
122 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glycemic control for diabetes mellitus, insulin sensitivity/resistance, lipidomics, metabolomics, obesity in diabetes, obesity/therapy, semaglutide, type 1 diabetes mellitus (t1dm), weight loss